CSL Limited (ASX: CSL) shares fell 3% Wednesday morning despite the biopharmaceutical giant hosting its research & development (R&D) investor update.
Indeed, it seems CSL shares have been caught up in a broad market sell-off despite delivering another promising operational and market update.
Who is CSL?
CSL is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900’s as the Commonwealth Serum Labratories , CSL was sold by the Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition.
Today, CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
What’s Going On?
CSL hosts its research & development investor briefing today.
CSL spends between 10% and 11% of its yearly revenue on the research and development of new drugs and vaccines. According to today’s update, CSL has nine products in Phase III trials.
Commenting on the market opportunity, CSL’s Chief Commercial Officer Bill Campbell provided an overview of the market for CSL and where it fits.
In 2018, CSL earned almost half ($3.14 billion) of its revenue from its immunoglobulin products, as can be seen above. Immunoglobulins are another way of saying antibodies.
In the past 12 months, CSL has launched privigen and Hizentra. These products are approved for use in 80 countries and 57 countries, respectively, and appear to be showing good early signs.
As can be seen in the chart above, CSL’s target market is huge. So despite already growing at an enviable pace over decades, it seems CSL could be expected to experience further growth over the long run.
Time to Put CSL Shares on Your Watchlist?
With a proven track record, industry-leading products and more in the pipeline, CSL should be on Australian investors’ watchlists.
Having said that, I don’t own CSL shares because I haven’t done enough work on its products to understand the opportunity, the risks and arrive at a reasonable valuation.
Fortunately for me there are plenty of other great ASX shares offering both dividends and growth…
The Rask Group's top expert investment analyst has just released a free report which reveals 3 proven ASX shares. They’ve proven themselves to be reliable dividend + growth shares over a decade. Access the report now.
Of course, past performance is not indicative of future performance but as he says in his free report, there are many reasons to keep a close watch on these 3 shares in 2019 and beyond.
Click here to access the free report. Absolutely no credit card details or payment required.
Disclaimer: Any information contained in this article is limited to general financial/investment advice only. The information has not taken into account your specific needs, goals or objectives, so please consider consulting a licenced and trusted adviser before acting on the information. Please read The Rask Group’s Financial Services Guide (FSG) for more information. This article is authorised by Owen Raszkiewicz of The Rask Group, which is a corporate authorised representative No. 1264179 of Strawman Pty Ltd (ACN: 610 908 211) (AFSL: 501 223).
The Pengana Private Equity Trust (sponsored)